Skip to main content
Accelsius Achieves Industry-Leading Thermal Milestones for Next-Generation AI Computing – Read more
Innventure - Creating companies to transform tomorrow.
Companies
Companies
PureCycle
AeroFlexx
Accelsius
Refinity
Our Companies
Press Release
Climb Channel Solutions Launches Global Partnership with Accelsius LLC
About
Our Team
Meet Innventure's world-class team of seasoned executives and entrepreneurs across industries.
Connect
What We Do
Optimize R&D investments with our unique technology commercialization approach.
Learn
How We Work
See how we systematically approach evaluating, commercializing, and advancing technologies.
Explore
Careers
Learn more about career opportunities at Innventure. Help transform technologies into companies.
Apply
News & Media
News & Media
News
Events
Insights
Featured Insight
How Scientific Thinking Can Revolutionize Business Strategy
ContactInvestors
Innventure - Creating companies to transform tomorrow.
Menu
Companies
Back
Companies
All Companies
PureCycle
AeroFlexx
Accelsius
Refinity
About
Back
About
Our Team
What We Do
How We Work
Careers
News & Media
Back
News & Media
News
Events
Insights
ContactInvestors
Insights

Embrace the Change

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.

Category

Company Building

Tags

Market Trends
Market Need
Technology Commercialization

Time to Read

1 min

Author

Dr. John Scott

Share

How does Innventure get customers to embrace change?

When introducing disruptive technology into the marketplace, the biggest challenge is to compel the customer to stop using the solution that they have been used to and switch to something different. While consumers may try something novel like pet rocks or hula hoops, businesses need a quantitatively compelling reason to switch gears.  

At Innventure, we have evolved to a model based on ICQVP – Immediate, Compelling, Quantitative Value Proposition. Here’s an example to illustrate. Prior to Innventure, some of our current leaders were working on a project together. That team created an automated microscope that could systematically search through anything that you could put on a slide (e.g., blood) looking for the proverbial needle in a haystack. Their task was to automate and dramatically improve the ability of a pathologist to find a few cancer cells against a matrix of millions of normal cells.  As is common knowledge, earlier and more reliable detection leads to earlier treatment resulting in savings for the healthcare system – yet, human pathologists can misdiagnose sometimes. In short, the team was able to reduce the diagnostic process from hours to minutes with nearly 100% identification – a leap forward in cellular diagnostics.  

Initially, when introducing this disruptive solution into the market, the team planned to sell instruments that would materially reduce the life cycle cost of patient care. They quantified this benefit to insurance companies and demonstrated that if the company bought a machine for a few hundred thousand dollars, they could save many millions of dollars in a few short years. However, the team quickly learned that the insurance companies would not pay for a system upfront that may yield a larger economic benefit to patients that could be in someone else’s insurance pool by the time those savings would have been realized.

That roadblock led the group to a business model that provided an immediate benefit to the payor while reducing the risk– a redesigned value proposition that provided the instrument to the payors for free but that included a revenue share for any new incremental dollars that the instrument was able to produce. Every time the instrument ran a reimbursable test, the team received a third of the revenue, and the client received two-thirds. This fundamental change in the business model is designed for rapid adoption and creating more value while significantly reducing risk for the clients. The benefits to the market were:

Immediate – Money received for every test that was run on the instrument

Compelling – Limited capital risk as it required no up-front investment

Quantitative Value Proposition – If reimbursement for a given test was $3,000; the client received 2/3 or $2,000.  The client was motivated to use this instrument as this was new revenue that was previously outsourced to reference laboratories. Additionally, the ability to identify cancer cells with significantly improved accuracy meant immediate savings for health care systems because it saved them the cost of follow-on treatment for false positive patients. In essence, they had been treating people who did not have disease.  

That lesson learned 25 years ago is now embedded into our business model, known as “ICQVP”.

‍

Related Insights

You May Also Like

All Insights

The Innventure Model Difference

Vertical Integration

Pardon the Disruption

For Multinational Corporations
innovate@innventure.com
For Investor Relations
investorrelations@innventure.com
For Press Inquiries
press@innventure.com
Learn
Our TeamWhat We DoHow We WorkCareers
Explore
All CompaniesPureCycleAeroFlexxAccelsiusRefinity
Engage
NewsInsightsEventsContactInvestors
Innventure.
© 2023. All Rights Reserved.
Privacy PolicyTerms of Use

Your Privacy is important to us

Customize your cookie preferences or click “Accept All” to agree to the storing of cookies on your device. View our Privacy Policy for more information.
Preferences
Accept
Deny
Privacy Preference Center

Below we list the different types of cookies that we use on the Site.  The specific cookies that we use, and the categories to which they belong, are available in the consent manager. To the extent any personal information is collected through cookies, our Privacy Policy applies and complements this Policy.

Always Allow Cookies
Close
Manage Consent Preferences
Required cookies enable you to navigate the Site and to use its services and features.  Without these absolutely necessary cookies, we may not be able to provide the Site or certain services or features, and the Site will not perform as smoothly for you as we would like it to.

These cookies are used to deliver advertising that is more relevant to you and your interests. They may also be used to limit the number of times you see an advertisement and measure the effectiveness of advertising campaigns. Advertising networks usually place them with the website operator’s permission.

These cookies allow us to analyze your use of the Site to evaluate and improve our performance, for example, by providing us information about how our site is used.

Reject AllConfirm My Choices
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.